Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Mashari Alzahrani"'
Management Strategies for Older Patients with Low-Risk Early-Stage Breast Cancer: A Physician Survey
Autor:
Mashari Alzahrani, Mark Clemons, Lynn Chang, Lisa Vendermeer, Angel Arnaout, Gail Larocque, Katherine Cole, Tina Hsu, Deanna Saunders, Marie-France Savard
Publikováno v:
Current Oncology, Vol 29, Iss 1, Pp 1-13 (2021)
When managing older patients with lower-risk hormone-receptor-positive (HR+), HER2 negative (HER2−) early-stage breast cancer (EBC), the harms and benefits of adjuvant therapies should be taken into consideration. A survey was conducted among Canad
Externí odkaz:
https://doaj.org/article/5af5145ba17a4a0baa6f785943263e70
Autor:
Sharon McGee, Mashari AlZahrani, Carol Stober, Terry L. Ng, Katherine Cole, Gail Larocque, Arif Awan, Sandeep Sehdev, John Hilton, Lisa Vandermeer, Brian Hutton, Gregory Pond, Deanna Saunders, Mark Clemons
Publikováno v:
Journal of Bone Oncology, Vol 27, Iss , Pp 100351- (2021)
Background: Despite the increasing use of adjuvant bisphosphonates for early stage breast cancer (EBC), little is known about the patient experience with such treatments. A patient survey was performed to identify current prescribing practices, perce
Externí odkaz:
https://doaj.org/article/f1411dede35d4fa1a6439a23035a2735
Autor:
Mashari AlZahrani, Mark Clemons, Lisa Vandermeer, Marta Sienkiewicz, Arif Ali Awan, Brian Hutton, Gregory R. Pond, Terry L. Ng
Publikováno v:
Journal of Bone Oncology, Vol 26, Iss , Pp 100339- (2021)
Background: There remain questions around the optimal use of bone-modifying agents (BMAs) in patients with bone metastases from breast and castration-resistant prostate cancer (CRPC). A physician survey was performed to identify current practices, as
Externí odkaz:
https://doaj.org/article/98d068926b794135b1df31a50383b99a
Autor:
Katherine Marie Cole, Mark Clemons, Sharon McGee, Mashari Alzahrani, Gail Larocque, Fiona MacDonald, Michelle Liu, Gregory R. Pond, Lucy Mosquera, Lisa Vandermeer, Brian Hutton, Ardelle Piper, Ricardo Fernandes, Khaled El Emam
Publikováno v:
Supportive Care in Cancer. 30:7397-7406
Purpose Machine learning (ML) is a powerful tool for interrogating datasets and learning relationships between multiple variables. We utilized a ML model to identify those early breast cancer (EBC) patients at highest risk of developing severe vasomo
Autor:
Bader Alshamsan, Ahmed Mostafa Gad, Maaz Kamal Alata, Mashari Alzahrani, Tusneem Elhassan, Jean Paul Atallah
Publikováno v:
Journal of Oncology. 2022:1-9
Background. Numerous chemotherapeutic agents have antitumor activity in recurrent/metastatic (R/M) nasopharyngeal cancer (NPC). Evidence of capecitabine’s effectiveness as monotherapy is limited. Capecitabine tolerability in solid malignancies has
Autor:
Katherine Marie Cole, Mark Clemons, Mashari Alzahrani, Michelle Liu, Gail Larocque, Fiona MacDonald, Brian Hutton, Ardelle Piper, Ricardo Fernandes, Gregory R. Pond, Lisa Vandermeer, Khaled El Emam, Sharon F. McGee
Publikováno v:
Supportive Care in Cancer
Background Despite the frequency of vasomotor symptoms (VMS) in patients with early breast cancer (EBC), their optimal management remains unknown. A patient survey was performed to determine perspectives on this important clinical challenge. Methods
Autor:
Lisa Vandermeer, Mark Clemons, Michelle Liu, Deanna Saunders, Mashari Alzahrani, Brian Hutton
Publikováno v:
Current Oncology
Current Oncology, Vol 28, Iss 337, Pp 3959-3977 (2021)
Current Oncology, Vol 28, Iss 337, Pp 3959-3977 (2021)
We reviewed patient and health care provider (HCP) surveys performed through the REaCT program. The REaCT team has performed 15 patient surveys (2298 respondents) and 13 HCP surveys (1033 respondents) that have addressed a broad range of topics in br
Publikováno v:
Supportive Care in Cancer. 29:7837-7843
A personalized risk model (PRM) that can categorize patients into high or low risk of ≥ grade 2 acute and/or delayed chemotherapy-induced nausea and vomiting (CINV) was previously developed. The current study assessed whether the PMR could accurate
Autor:
Sandeep Sehdev, Brian Hutton, Lisa Vandermeer, Christina Canil, Arif Awan, Mark Clemons, Noa Shani Shrem, Marta Sienkiewicz, Sharon F. McGee, Terry L. Ng, Deanna Saunders, Gregory R. Pond, Mashari Alzahrani
Publikováno v:
Supportive Care in Cancer
Background Optimal use of bone-modifying agent (BMA) therapy in patients with bone metastases from breast and castrate-resistant prostate cancer (CRPC) is evolving. Methods Patients receiving BMA for bone metastases from breast or CRPC were surveyed.
Autor:
Terry L. Ng, Lisa Vandermeer, Gregory R. Pond, Marta Sienkiewicz, Brian Hutton, Mashari Alzahrani, Arif Awan, Mark Clemons
Publikováno v:
Cancer Research. 81:PS14-18
Background: Despite extensive use of bone modifying agents (BMA) in patients with bone metastases from breast cancer (BC), the optimal choice, frequency, and duration of BMA treatment remains unclear. A physician survey was performed to identify curr